The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period. [Status: ACTIVE_NOT_RECRUITING | Phase: PHASE3 | Sponsor: DBV Technologies]
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
|ClinicalTrials.gov